Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M0Revenue $M0Net Margin (%)0Z-Score0
Enterprise Value $M0EPS $0Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %ROA % (ttm)0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with GCVRZ

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GCVRZMario Gabelli 2014-03-31 Reduce$0.3 - $0.47
($0.37)
$ 0.4522%Reduce -35.1%631,351
GCVRZMichael Price 2013-12-31 Add0.06%$0.32 - $2.04
($1.21)
$ 0.45-63%Add 31.68%5,300,000
GCVRZJean-Marie Eveillard 2013-12-31 Add$0.32 - $2.04
($1.21)
$ 0.45-63%Add 16262.5%229,402
GCVRZDavid Abrams 2013-12-31 Reduce-3.07%$0.32 - $2.04
($1.21)
$ 0.45-63%Reduce -62.61%11,658,873
GCVRZMario Gabelli 2012-12-31 Reduce-0.01%$1.67 - $1.89
($1.77)
$ 0.45-75%Reduce -26.21%1,188,148
GCVRZMichael Price 2012-03-31 Add0.19%$1.25 - $1.37
($1.22)
$ 0.45-63%Add 29.41%4,400,000
GCVRZJean-Marie Eveillard 2011-12-31 Reduce$0.89 - $1.34
($1.12)
$ 0.45-60%Reduce -99.53%1,402
GCVRZMichael Price 2011-09-30 Add0.26%$0.99 - $2.56
($1.4)
$ 0.45-68%Add 70%3,400,000
GCVRZJean-Marie Eveillard 2011-09-30 Reduce-0.01%$0.99 - $2.56
($1.4)
$ 0.45-68%Reduce -81.3%301,402
GCVRZMichael Price 2011-06-30 Buy 0.7%$2.29 - $2.63
($2.44)
$ 0.45-82%New holding, 2000000 sh.2,000,000
GCVRZRichard Perry 2011-06-30 Buy 0.41%$2.29 - $2.63
($2.44)
$ 0.45-82%New holding, 5726911 sh.5,726,911
GCVRZMario Gabelli 2011-06-30 Buy 0.04%$2.29 - $2.63
($2.44)
$ 0.45-82%New holding, 2288150 sh.2,288,150
GCVRZJean-Marie Eveillard 2011-06-30 Buy 0.02%$2.29 - $2.63
($2.44)
$ 0.45-82%New holding, 1611585 sh.1,611,585
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GCVRZ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GCVRZ Jean-Marie Eveillard 2014-03-31229,402 0
GCVRZ Michael Price 2014-03-315,275,000 0.2-0.47%
GCVRZ Mario Gabelli 2014-03-31631,351 0-35.1%
Premium Most recent portfolio changes are included for Premium Members only!


GCVRZ: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about GCVRZ :

    Quarterly/Annual Reports about GCVRZ:

      News about GCVRZ:

      Articles On GuruFocus.com
      No related article found.

      More From Other Websites
      Adidas pulls European stocks lower Jul 31 2014
      Europe shares steady at open; Sanofi rises after results Jul 31 2014
      Sanofi dengue vaccine promising but questions remain Jul 11 2014
      European shares retreat after weak German data Jul 07 2014
      European shares retreat after weak German data Jul 07 2014
      GLOBAL MARKETS-Dollar clings onto gains as equities prepare for earnings Jul 07 2014
      European shares retreat after weak German data Jul 07 2014
      European shares edge lower after German data miss Jul 07 2014
      European shares held back by weak German data Jul 07 2014
      Roche biotech drug offers new way to fight asthma Jul 02 2014
      GlaxoSmithKline confirm existence of sex tape in China Jun 30 2014
      AstraZeneca plc’s Not So Secret Weapon Jun 16 2014
      GSK invites private equity to bid for older drugs -sources May 29 2014
      British cost body recommends Sanofi MS drug Lemtrada May 27 2014
      A bitter pill as China crackdowns squeeze pharma margins May 26 2014
      A bitter pill as China crackdowns squeeze pharma margins May 25 2014
      A bitter pill as China crackdowns squeeze pharma margins May 24 2014
      AstraZeneca tows Britain's FTSE lower after takeover snub May 19 2014
      AstraZeneca tows Britain's FTSE lower after takeover snub May 19 2014
      AstraZeneca pegs back Britain's FTSE after takeover snub May 19 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide